+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
Uveitis Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Uveitis Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more